Nanotechnology-Based Therapeutics for Renal Injury Management

Nanotechnology-based therapeutics have emerged as a transformative approach to address renal injury by exploiting the unique physicochemical properties of nanoscale materials. By engineering nanoparticles, drug conjugates and nanozymes with tailored size, surface charge and targeting ligands, researchers aim to enhance renal accumulation, overcome biological barriers and deliver antioxidants or bioactive agents directly to injured nephron segments. The primary focus has been on mitigating oxidative stress and inflammation, two central mechanisms driving acute kidney injury and chronic renal diseases. Strategies include antioxidant nanoclusters, organelle-targeted carriers and ligand-directed delivery to glomerular or tubular cells, offering improved biocompatibility, reduced off-target toxicity and the potential for real-time imaging guidance. Collectively, these advances point to a new era of precision nanomedicine for renal repair and functional restoration.

Research from Nature Portfolio

Recent studies have demonstrated the potential of antibody fragment drug conjugates to enhance renal targeting and therapeutic efficacy in diabetic nephropathy. One approach employed F(ab′)2 fragments directed against VEGFR2 linked to a mitochondria-targeted antioxidant peptide, resulting in superior kidney accumulation and glomerular repair compared with intact antibodies. Foundational work on polyoxometalate nanoclusters revealed that molybdenum-based nanoscale antioxidants preferentially localise in renal tissue, effectively scavenging reactive oxygen species and ameliorating acute kidney injury in animal models. In parallel, albumin-based nanoparticles have been used to deliver celastrol specifically to mesangial cells, thereby reducing systemic toxicity while alleviating proteinuria and glomerular inflammation in experimental glomerulonephritis.

Nanotechnology-Based Therapeutics for Renal Injury Management publication trend

The graph below shows the total number of articles in nanotechnology-based therapeutics for renal injury management across all publications each year (not limited to Nature Index journals).

Technical terms

Nanoparticles: Nanoscale particles (1–100 nm) engineered to deliver therapeutic agents and modulate biological processes.

Reactive oxygen species (ROS): Highly reactive molecules containing oxygen that can cause cellular damage and drive inflammation.

Glomerular filtration barrier: A tri-layered structure (endothelium, basement membrane, podocytes) that governs blood filtration in the kidney.

F(ab′)2 antibody fragment drug conjugate: A bifunctional molecule comprising two antigen-binding fragments linked to a therapeutic payload.

Polyoxometalate (POM) nanocluster: A metal-oxygen cluster with variable valence states that can function as a catalytic antioxidant at the nanoscale.

NLRP3 inflammasome: A multiprotein complex that regulates activation of inflammatory cytokines in response to cellular stress.

Mitochondria-targeting moiety: A chemical group or peptide that directs nanocarriers to the mitochondrial compartment within cells.

References

1. Anti-VEGFR2 F(ab′)2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy. Nature Communications (2023).
2. Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nature Communications (2018).
3. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis. Nature Communications (2017).
4. Engineered nanodrug targeting oxidative stress for treatment of acute kidney injury. Exploration (2023).
5. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury. Theranostics (2020).
6. Selenium nanoparticles alleviate ischemia reperfusion injury-induced acute kidney injury by modulating GPx-1/NLRP3/Caspase-1 pathway. Theranostics (2022).